Gea receives accolade for the aseptic blow-fill-cap technology, ABF 1.2, with FDA certification

In July 2018, the U.S. Food and Drug Administration (FDA) awarded GEA a letter of no objection (LONO) for its ABF 1.2 technology, an integrated blowing, filling and capping solution featuring a fully aseptic rotary blowing machine. It is the only system equipped with a 100% aseptic blower that is allowed to produce shelf-stable low acid (LA) beverages free from preservatives for distribution at ambient temperature in the U.S. market.

The FDA testing is considered one of the most comprehensive validation protocols available in the aseptic beverage market. Their stringent requirements ensure enhanced product safety, and their approval is highly valued even outside the U.S. The FDA clearance confirms that GEA’s ABF 1.2 technology ensures maximum sterilisation efficiency and reliability during every step of sensitive beverage bottling. Gea successfully passed the validation tests which were performed on an ABF 1.2 system installed in the U.S. – and which is now already producing and delivering shelf-stable liquid dairy products to the North-American market.

The Gea solution is based on an integrated blowing, filling and capping process that runs within a 100% aseptic environment. Thanks to the microbiological isolator, Gea ABF 1.2 aseptically blows preforms that have been previously treated with hydrogen peroxide vapor (VHP). The result is a single zone sterilisation process that requires no water and fewer chemicals.
Visit Gea Group AG